CL2017000026A1 - Formas de dosificación farmacéutica - Google Patents

Formas de dosificación farmacéutica

Info

Publication number
CL2017000026A1
CL2017000026A1 CL2017000026A CL2017000026A CL2017000026A1 CL 2017000026 A1 CL2017000026 A1 CL 2017000026A1 CL 2017000026 A CL2017000026 A CL 2017000026A CL 2017000026 A CL2017000026 A CL 2017000026A CL 2017000026 A1 CL2017000026 A1 CL 2017000026A1
Authority
CL
Chile
Prior art keywords
pharmaceutical dosage
dosage forms
forms
pirrolo
dihidro
Prior art date
Application number
CL2017000026A
Other languages
English (en)
Inventor
Stefania Beato
Peggy Quinton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017000026A1 publication Critical patent/CL2017000026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A FORMAS DE DOSIFICACIÓN FARMACÉUTICA PARA ADMINISTRACIÓN ORAL QUE COMPRENDEN EL FÁRMACO 4-[(5R)-6,7-DIHIDRO-5H-PIRROLO[1,2-C]IMIDAZOL-5-IL]-3-FLUOROBENZONITRILO O CUALQUIER SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO Y A PROCESOS PARA PRODUCIR DICHAS FORMAS SÓLIDAS DE DOSIFICACIÓN FARMACÉUTICA.</p>
CL2017000026A 2014-07-07 2017-01-06 Formas de dosificación farmacéutica CL2017000026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462021271P 2014-07-07 2014-07-07

Publications (1)

Publication Number Publication Date
CL2017000026A1 true CL2017000026A1 (es) 2017-07-28

Family

ID=53610933

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000026A CL2017000026A1 (es) 2014-07-07 2017-01-06 Formas de dosificación farmacéutica

Country Status (29)

Country Link
US (2) US10143680B2 (es)
EP (2) EP3166596B1 (es)
JP (2) JP6731136B2 (es)
KR (1) KR102468610B1 (es)
CN (1) CN106470704B (es)
AR (1) AR101116A1 (es)
AU (1) AU2015287336B2 (es)
BR (1) BR112016030243B1 (es)
CA (1) CA2954393C (es)
CL (1) CL2017000026A1 (es)
CY (1) CY1120749T1 (es)
DK (1) DK3166596T3 (es)
EA (2) EA201991359A1 (es)
EC (1) ECSP17008187A (es)
ES (1) ES2686704T3 (es)
HR (1) HRP20181406T1 (es)
HU (1) HUE039037T2 (es)
IL (1) IL249374B (es)
LT (1) LT3166596T (es)
MX (1) MX2016017315A (es)
PE (1) PE20170201A1 (es)
PH (1) PH12016502540A1 (es)
PL (1) PL3166596T3 (es)
PT (1) PT3166596T (es)
SG (1) SG11201610227TA (es)
SI (1) SI3166596T1 (es)
TN (1) TN2016000557A1 (es)
TW (1) TWI707682B (es)
WO (1) WO2016005880A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11992479B2 (en) 2018-05-03 2024-05-28 Damian Pharma Ag R-fadrozole for use in the treatment of aldostonerism

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191487A1 (en) 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
CL2008000727A1 (es) * 2007-03-13 2008-10-17 Takeda Pharmaceutical Granulo compuesto por 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluorobenzonitrilo o una de sus sales y un aditivo que no comprende celulosa microcristalina; preparacion solida; comprimido y procedimi
MX2012008212A (es) * 2010-01-14 2012-08-03 Novartis Ag Uso de un agente modificador de hormonas suprarrenales.
AU2011293135A1 (en) * 2010-08-27 2013-04-11 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
AU2012304693B2 (en) * 2011-09-08 2016-03-31 Mereo Biopharma 2 Limited Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
SI2804863T1 (sl) * 2012-01-17 2016-05-31 Novartis Ag Nove oblike in soli zaviralca sinteze ali aromataze dihidropropirolo(1,2-c)imidazolil aldosterona
WO2013126326A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof
CA2869442C (en) * 2012-04-12 2020-09-08 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern

Also Published As

Publication number Publication date
EP3412278A1 (en) 2018-12-12
EP3166596B1 (en) 2018-06-06
KR102468610B1 (ko) 2022-11-21
HRP20181406T1 (hr) 2018-10-19
AU2015287336B2 (en) 2018-06-14
PL3166596T3 (pl) 2018-11-30
IL249374A0 (en) 2017-02-28
LT3166596T (lt) 2018-09-25
IL249374B (en) 2021-09-30
EP3166596A1 (en) 2017-05-17
BR112016030243A2 (pt) 2017-08-22
JP6731136B2 (ja) 2020-07-29
EA201991359A1 (ru) 2020-03-13
HUE039037T2 (hu) 2018-12-28
TWI707682B (zh) 2020-10-21
SI3166596T1 (sl) 2018-10-30
KR20170029491A (ko) 2017-03-15
CA2954393C (en) 2022-07-19
JP2019194221A (ja) 2019-11-07
TW201613586A (en) 2016-04-16
US10709691B2 (en) 2020-07-14
CN106470704A (zh) 2017-03-01
US20170202808A1 (en) 2017-07-20
MX2016017315A (es) 2017-04-27
CA2954393A1 (en) 2016-01-14
WO2016005880A1 (en) 2016-01-14
PE20170201A1 (es) 2017-04-08
CY1120749T1 (el) 2019-12-11
PH12016502540A1 (en) 2017-04-10
ES2686704T3 (es) 2018-10-19
TN2016000557A1 (en) 2018-04-04
JP2017520590A (ja) 2017-07-27
PT3166596T (pt) 2018-10-19
EA033685B1 (ru) 2019-11-15
AR101116A1 (es) 2016-11-23
US10143680B2 (en) 2018-12-04
AU2015287336A1 (en) 2017-01-12
BR112016030243B1 (pt) 2023-04-11
CN106470704B (zh) 2020-07-31
ECSP17008187A (es) 2018-03-31
DK3166596T3 (en) 2018-09-10
US20190060283A1 (en) 2019-02-28
EA201790140A1 (ru) 2017-05-31
SG11201610227TA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
MX2021010306A (es) Gamma-carbolinas heterociclicas fusionadas sustituidas, composiciones farmaceuticas y metodos de uso.
MX2019007474A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
MX2016013046A (es) Compuestos organicos.
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
BR112017028140A2 (pt) formulações farmacêuticas
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
UY36124A (es) Derivados de carboxamida
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
WO2015001541A3 (en) Pharmaceutical film composition
BR112017022856A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán
CL2017000026A1 (es) Formas de dosificación farmacéutica
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
BR112017022855A2 (pt) combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó
UA97716U (uk) Лікарський засіб у формі сиропу, що містить фенспіриду гідрохлорид
CL2018001236A1 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo.